Oncolytics Biotech (ONCY) FCF Margin (2009 - 2025)

Oncolytics Biotech's (ONCY) quarterly FCF Margin came in at 6523.08% in Q3 2025, up 2425948.0% year-on-year from N/an in Q3 2024, and up 136.78% on a QoQ basis from 17736.39% in Q3 2024.

Oncolytics Biotech (ONCY) FCF Margin (2009 - 2025) Analysis & Trends

Oncolytics Biotech (ONCY) has 10 years of FCF Margin data on file, last reported at 6523.08% in Q3 2025.

  • On a quarterly basis, FCF Margin rose 2425948.0% year-over-year to 6523.08% in Q3 2025; TTM through Sep 2025 was 28.76%, a 1044.0% decrease from a year earlier, with the FY2018 full-year figure at 87.61%, changed N/A from the prior year.
  • FCF Margin for Q3 2025 stood at 6523.08%, up from 17736.39% in the prior quarter.
  • Over the last five years, FCF Margin for ONCY reached as high as 6523.08% in Q3 2025 and fell as low as 17736.39% in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 10.45%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 43.35%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 23.53%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Oncolytics Biotech 372.40 Mn 372.40 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 6,523.08%
Sep 30, 2024 -17,736.39%
Sep 30, 2020 -14.67%
Jun 30, 2020 -13.04%
Mar 31, 2020 -8.52%
Sep 30, 2019 -36.73%
Jun 30, 2019 -38.63%
Mar 31, 2019 0.00%
Dec 31, 2018 32.07%
Sep 30, 2018 21,874.36%
Jun 30, 2017 0.00%
Jun 30, 2016 368.40%
Jun 30, 2011 351.03%
Sep 30, 2010 -1,599.14%
Jun 30, 2010 -665.64%
Mar 31, 2009 -43.04%